Authors: Annie Kennedy and Joff Masukawa. Rare diseases impact 1 in 10 Americans, and over 400 million people worldwide. The current development and FDA approval process can cost hundreds of millions of dollars – and take an average of 15 years – to develop one therapy. For the 30% of children diagnosed with a rare [...]
PRESS RELEASE: IVI Announces Grant to National Health Council, National Alliance of Healthcare Purchaser Coalitions to Improve Value Assessment
Goal: Identify Areas of Consensus to Ultimately Make the Value Assessment Process Useful to Those Who Receive and Pay for Care Alexandria, VA – July 20, 2020 – The Innovation and Value Initiative (IVI), a non-profit research organization dedicated to improving the science and practice of value assessment, announced today it is awarding a grant [...]
Central to IVI’s work is ensuring patient perspectives are included at the front of all value assessments. This short video explains why and how IVI incorporates lived experience in its modeling.
IVI's Jennifer Bright and Mike Thompson of the National Alliance for Healthcare Purchasers share how employers can use depression as a "test case" for thinking about how to improve the value assessment process, so that we can apply a "purchaser-patient" lens up front. Read the full article on Employers Benefit News here.
The COVID-19 pandemic is raising new questions about how we approach value assessment. As always, IVI urges experts to use transparency, real world data, and seek consensus. Sam Nussbaum, President of the IVI Board of Directors, shares his thoughts in a commentary in STAT. Read the full commentary here.
Authors: Alan Balch and Donna Cryer The vast majority of experts agree that we could, and should, be doing a lot more to include input from patients in value assessment, from conceptualization to data inputs to implementation. The crux of the problem is that in today’s world, we end up with models that assign a [...]
IVI's Jennifer Bright and Amy Miller, former CEO of the Society for Women's Health Research, explain why patient heterogeneity is crucial to consider in any value assessment method. Read the full article here.
Previewing their panel discussion at ISPOR 2020, Lou Garrison and Leah Howard discuss what’s needed to address gaps on value assessment. View the short video clip here.
The national dialogue on value in health care is bringing to the forefront the limitations of current value assessment methods and gaps in real world data to inform decision-making. IVI seeks to engage a wider group of stakeholders to inform priorities in methods research and to invest resources and expertise in improving value assessment. Toward [...]
Authors: Patricia Deverka, Jennifer Bright, Louis Garrison, Samuel Nussbaum We have seen the COVID-19 pandemic decimate people’s lives, health care systems, and the global and US economy, with investments by the US government exceeding $4 trillion dollars and with unemployment approaching 20%. In recent days, numerous articles have speculated on the pricing for Gilead’s new [...]